Log In
Print this Print this

acamprosate (SNC-102)

  Manage Alerts
Collapse Summary General Information
Company Synchroneuron Inc.
DescriptionSustained-release formulation of acamprosate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationHyperkinetic movement disorder
Indication DetailsTreat tardive dyskinesia
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today